6
|
Ruprecht N, Hungerbühler MN, Böhm IB, Heverhagen JT. Improved identification of DNA double strand breaks: γ-H2AX-epitope visualization by confocal microscopy and 3D reconstructed images. RADIATION AND ENVIRONMENTAL BIOPHYSICS 2019; 58:295-302. [PMID: 30799523 DOI: 10.1007/s00411-019-00778-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Accepted: 01/22/2019] [Indexed: 06/09/2023]
Abstract
Currently, in the context of radiology, irradiation-induced and other genotoxic effects are determined by visualizing DSB-induced DNA repair through γ-H2AX immunofluorescence and direct counting of the foci by epifluorescence microscopy. This procedure, however, neglects the 3D nature of the nucleus. The aim of our study was to use confocal microscopy and 3D reconstructed images to improve documentation and analysis of γ-H2AX fluorescence signals after diagnostic examinations. Confluent, non-dividing MRC-5 lung fibroblasts were irradiated in vitro with a Cs-137 source and exposed to radiation doses up to 1000 mGy before fixation and staining with an antibody recognizing the phosphorylated histone variant γ-H2AX. The 3D distribution of γ-H2AX foci was visualized using confocal laser scanning microscopy. 3D reconstruction of the optical slices and γ-H2AX foci counting were performed using Imaris Image Analysis software. In parallel, γ-H2AX foci were counted visually by epifluorescence microscopy. In addition, whole blood was exposed ex vivo to the radiation doses from 200 to 1600 mGy. White blood cells (WBCs) were isolated and stained for γ-H2AX. In fibroblasts, epifluorescence microscopy alone visualized the entirety of fluorescence signals as integral, without correct demarcation of single foci, and at 1000 mGy yielded on average 11.1 foci by manual counting of 2D images in comparison to 36.1 foci with confocal microscopy and 3D reconstruction (p < 0.001). The procedure can also be applied for studies on WBCs. In contrast to epifluorescence microscopy, confocal microscopy and 3D reconstruction enables an improved identification of DSB-induced γ-H2AX foci, allowing for an unbiased, ameliorated quantification.
Collapse
Affiliation(s)
- Nico Ruprecht
- Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland.
- Department of BioMedical Research, University of Bern, Bern, Switzerland.
| | - Martin N Hungerbühler
- Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
- Department of BioMedical Research, University of Bern, Bern, Switzerland
| | - Ingrid B Böhm
- Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
- Department of BioMedical Research, University of Bern, Bern, Switzerland
| | - Johannes T Heverhagen
- Department of Diagnostic, Interventional, and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, 3010, Bern, Switzerland
- Department of BioMedical Research, University of Bern, Bern, Switzerland
| |
Collapse
|
7
|
Hall J, Jeggo PA, West C, Gomolka M, Quintens R, Badie C, Laurent O, Aerts A, Anastasov N, Azimzadeh O, Azizova T, Baatout S, Baselet B, Benotmane MA, Blanchardon E, Guéguen Y, Haghdoost S, Harms-Ringhdahl M, Hess J, Kreuzer M, Laurier D, Macaeva E, Manning G, Pernot E, Ravanat JL, Sabatier L, Tack K, Tapio S, Zitzelsberger H, Cardis E. Ionizing radiation biomarkers in epidemiological studies - An update. MUTATION RESEARCH. REVIEWS IN MUTATION RESEARCH 2017; 771:59-84. [PMID: 28342453 DOI: 10.1016/j.mrrev.2017.01.001] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Accepted: 01/09/2017] [Indexed: 01/13/2023]
Abstract
Recent epidemiology studies highlighted the detrimental health effects of exposure to low dose and low dose rate ionizing radiation (IR): nuclear industry workers studies have shown increased leukaemia and solid tumour risks following cumulative doses of <100mSv and dose rates of <10mGy per year; paediatric patients studies have reported increased leukaemia and brain tumours risks after doses of 30-60mGy from computed tomography scans. Questions arise, however, about the impact of even lower doses and dose rates where classical epidemiological studies have limited power but where subsets within the large cohorts are expected to have an increased risk. Further progress requires integration of biomarkers or bioassays of individual exposure, effects and susceptibility to IR. The European DoReMi (Low Dose Research towards Multidisciplinary Integration) consortium previously reviewed biomarkers for potential use in IR epidemiological studies. Given the increased mechanistic understanding of responses to low dose radiation the current review provides an update covering technical advances and recent studies. A key issue identified is deciding which biomarkers to progress. A roadmap is provided for biomarker development from discovery to implementation and used to summarise the current status of proposed biomarkers for epidemiological studies. Most potential biomarkers remain at the discovery stage and for some there is sufficient evidence that further development is not warranted. One biomarker identified in the final stages of development and as a priority for further research is radiation specific mRNA transcript profiles.
Collapse
Affiliation(s)
- Janet Hall
- Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Univ Lyon, Université Claude Bernard, Lyon 1, Lyon, F-69424, France.
| | - Penny A Jeggo
- Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9RQ, United Kingdom
| | - Catharine West
- Translational Radiobiology Group, Institute of Cancer Sciences, The University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, M20 4BX, United Kingdom
| | - Maria Gomolka
- Federal Office for Radiation Protection, Department of Radiation Protection and Health, D-85764 Neuherberg, Germany
| | - Roel Quintens
- Radiobiology Unit, Belgian Nuclear Research Centre, SCK·CEN, B-2400 Mol, Belgium
| | - Christophe Badie
- Cancer Mechanisms and Biomarkers group, Radiation Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, United Kingdom
| | - Olivier Laurent
- Institut de Radioprotection et de Sûreté Nucléaire, F-92260 Fontenay-aux-Roses, France
| | - An Aerts
- Radiobiology Unit, Belgian Nuclear Research Centre, SCK·CEN, B-2400 Mol, Belgium
| | - Nataša Anastasov
- Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Institute of Radiation Biology, D-85764 Neuherberg, Germany
| | - Omid Azimzadeh
- Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Institute of Radiation Biology, D-85764 Neuherberg, Germany
| | - Tamara Azizova
- Southern Urals Biophysics Institute, Clinical Department, Ozyorsk, Russia
| | - Sarah Baatout
- Radiobiology Unit, Belgian Nuclear Research Centre, SCK·CEN, B-2400 Mol, Belgium; Cell Systems and Imaging Research Group, Department of Molecular Biotechnology, Ghent University, B-9000 Ghent, Belgium
| | - Bjorn Baselet
- Radiobiology Unit, Belgian Nuclear Research Centre, SCK·CEN, B-2400 Mol, Belgium; Pole of Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, B-1200 Brussels, Belgium
| | - Mohammed A Benotmane
- Radiobiology Unit, Belgian Nuclear Research Centre, SCK·CEN, B-2400 Mol, Belgium
| | - Eric Blanchardon
- Institut de Radioprotection et de Sûreté Nucléaire, F-92260 Fontenay-aux-Roses, France
| | - Yann Guéguen
- Institut de Radioprotection et de Sûreté Nucléaire, F-92260 Fontenay-aux-Roses, France
| | - Siamak Haghdoost
- Centre for Radiation Protection Research, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, SE 106 91 Stockholm, Sweden
| | - Mats Harms-Ringhdahl
- Centre for Radiation Protection Research, Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, SE 106 91 Stockholm, Sweden
| | - Julia Hess
- Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Institute of Radiation Biology, D-85764 Neuherberg, Germany
| | - Michaela Kreuzer
- Federal Office for Radiation Protection, Department of Radiation Protection and Health, D-85764 Neuherberg, Germany
| | - Dominique Laurier
- Institut de Radioprotection et de Sûreté Nucléaire, F-92260 Fontenay-aux-Roses, France
| | - Ellina Macaeva
- Radiobiology Unit, Belgian Nuclear Research Centre, SCK·CEN, B-2400 Mol, Belgium; Cell Systems and Imaging Research Group, Department of Molecular Biotechnology, Ghent University, B-9000 Ghent, Belgium
| | - Grainne Manning
- Cancer Mechanisms and Biomarkers group, Radiation Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Chilton, Didcot, United Kingdom
| | - Eileen Pernot
- INSERM U897, Université de Bordeaux, F-33076 Bordeaux cedex, France
| | - Jean-Luc Ravanat
- Laboratoire des Lésions des Acides Nucléiques, Univ. Grenoble Alpes, INAC-SCIB, F-38000 Grenoble, France; Commissariat à l'Énergie Atomique, INAC-SyMMES, F-38000 Grenoble, France
| | - Laure Sabatier
- Commissariat à l'Énergie Atomique, BP6, F-92265 Fontenay-aux-Roses, France
| | - Karine Tack
- Institut de Radioprotection et de Sûreté Nucléaire, F-92260 Fontenay-aux-Roses, France
| | - Soile Tapio
- Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Institute of Radiation Biology, D-85764 Neuherberg, Germany
| | - Horst Zitzelsberger
- Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Institute of Radiation Biology, D-85764 Neuherberg, Germany
| | - Elisabeth Cardis
- Barcelona Institute of Global Health (ISGlobal), Centre for Research in Environmental Epidemiology, Radiation Programme, Barcelona Biomedical Research Park, 08003 Barcelona, Spain; Universitat Pompeu Fabra (UPF) (MTD formerly), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
| |
Collapse
|
8
|
Cheezum MK, Redon CE, Burrell AS, Kaviratne AS, Bindeman J, Maeda D, Balmakhtar H, Pezel A, Wisniewski P, Delacruz P, Nguyen B, Bonner WM, Villines TC. Effects of Breast Shielding during Heart Imaging on DNA Double-Strand-Break Levels: A Prospective Randomized Controlled Trial. Radiology 2016; 281:62-71. [PMID: 27082782 PMCID: PMC5047130 DOI: 10.1148/radiol.2016152301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Purpose To examine the effect of breast shielding on blood lymphocyte deoxyribonucleic acid (DNA) double-strand-break levels resulting from in vivo radiation and ex vivo radiation at breast-tissue level, and the effect of breast shielding on image quality. Materials and Methods The study was approved by institutional review and commpliant with HIPAA guidelines. Adult women who underwent 64-section coronary computed tomographic (CT) angiography and who provided informed consent were prospectively randomized to the use (n = 50) or absence (n = 51) of bismuth breast shields. Peripheral blood samples were obtained before and 30 minutes after in vivo radiation during CT angiography to compare DNA double-strand-break levels by γ-H2AX immunofluorescence in blood lymphocytes. To estimate DNA double-strand-break induction at breast-tissue level, a blood sample was taped to the sternum for ex vivo radiation with or without shielding. Data were analyzed by linear regression and independent sample t tests. Results Breast shielding had no effect on DNA double-strand-break levels from ex vivo radiation of blood samples under shields at breast-tissue level (unadjusted regression: β = .08; P = .43 versus no shielding), or in vivo radiation of circulating lymphocytes (β = -.07; P = .50). Predictors of increased DNA double-strand-break levels included total radiation dose, increasing tube potential, and tube current (P < .05). With current radiation exposures (median, 3.4 mSv), breast shielding yielded a 33% increase in image noise and 19% decrease in the rate of excellent quality ratings. Conclusion Among women who underwent coronary CT angiography, breast shielding had no effect on DNA double-strand-break levels in blood lymphocytes exposed to in vivo radiation, or ex vivo radiation at breast-tissue level. At present relatively low radiation exposures, breast shielding contributed to an increase in image noise and a decline in image quality. The findings support efforts to minimize radiation by primarily optimizing CT settings. (©) RSNA, 2016 Clinical trial registration no. NCT02617888 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Michael K. Cheezum
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Christophe E. Redon
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Allison S. Burrell
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Anthony S. Kaviratne
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Jody Bindeman
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Daisuke Maeda
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Houria Balmakhtar
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Ashly Pezel
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Piotr Wisniewski
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Panfilo Delacruz
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Binh Nguyen
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - William M. Bonner
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| | - Todd C. Villines
- From the Department of Medicine (Cardiology Service) (M.K.C., A.S.K., J.B., T.C.V.) and Department of Radiology (B.N.), Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889; Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Md (C.E.R., A.S.B., D.M., H.B., W.M.B.); Institute of Biomedical Sciences, The George Washington University, Washington, DC (A.S.B.); George Mason University, Fairfax, Va (H.B.); Uniformed Services University of Health Sciences, Bethesda, Md (A.P., P.W.); and Department of Medicine, San Antonio Military Medical Center, San Antonio, Tex (P.D.)
| |
Collapse
|